Cancellation of state registration. Vinpocetine-ESCOM

June 14, 2017
Active substances:
Trade names:
ICD-10:
V.F00-F09.F01    Vascular dementia
VI.G40-G47.G45    Transitory transient cerebral ischemic attacks [attacks] and related syndromes
VI.G40-G47.G45.0    Syndrome of vertebrobasilar arterial system
VII.H30-H36.H34    Vascular occlusion of the retina
VII.H30-H36.H35.0    Background retinopathy and retinal vascular changes
VIII.H80-H83.H81.0    Ménière's disease
VIII.H90-H95.H93.0    Degenerative and vascular diseases of the ear
IX.I60-I69.I61    Intracerebral haemorrhage
IX.I60-I69.I63    Cerebral infarction
IX.I60-I69.I67.2    Cerebral atherosclerosis
IX.I60-I69.I67.4    Hypertensive encephalopathy
IX.I60-I69.I69    Effects of cerebrovascular disease
XIX.T90-T98.T90    Consequences of head injuries
Vinpocetine, Vinpocetine-ESCOM, cerebral circulatory insufficiency, vascular dementia, cerebrovascular atherosclerosis, treatment of head injuries, stroke treatment, retinal vascular disease, Meniere's disease, tinnitus, decreased hearing acuity

The Ministry of Health of the Russian Federation in accordance with articles 29 and 32 of the Federal Law of 12.04.2010 No. 61-FZ "On the circulation of medicines" decided to abolish state registration and exclude from the state register of medicinal products for medical use of the medicinal product (registration certificate LP- 000662 dated September 28, 2011, issued by NGO "ESKOM", Russia):

Vinpocetine-ESCOM (trade name of the medicinal product)

Vinpocetine (international non-proprietary, or grouping, or chemical name medicinal product)

concentrate for solution for infusion, 5 mg / ml (dosage form, dosage)

OAO NTZh "ESKOM", Russia 355107,Stavropol, Staromarevskoe highway, 9 G (name and address of the place of production)

in connection with the non-confirmation of the state registration of the medicinal product for medical use according to the results of the examination of the quality of the medicinal product and the examination of the relationship of the expected benefit to the possible risk of drug use.